Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
申请人:Elan Pharmaceuticals, Inc.
公开号:US06545003B1
公开(公告)日:2003-04-08
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
揭示了能够结合VLA-4的化合物。其中某些化合物还能抑制白细胞粘附,特别是通过VLA-4介导的白细胞粘附。这些化合物在治疗哺乳动物患者(例如人类)的炎症性疾病方面非常有用,如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可以用于治疗炎症性脑部疾病,如多发性硬化症。